Genmab A/S (CPH:GEN), a biotechnology company specialising in the creation and development of differentiated antibody therapeutics for the treatment of cancer, reported on Tuesday that worldwide net sales of DARZALEX (daratumumab), as reported by Johnson & Johnson, were USD774m in the second quarter of 2019, up by approximately 51% as compared to USD511m in the second quarter of 2018.

Out of the the second quarter of 2019 worldwide net sales, USD369m was the net sales in US and USD405m in the rest of the world.

Also, Johnson & Johnson reported worldwide operational DARZALEX sales growth (excluding impact of foreign currency movements) between the two second quarter periods in 2018 and 2019, respectively, of approximately 57%.

According to Johnson & Johnson, sales in the second quarter of 2019 included a one-time adjustment outside the US related to the completion of pricing and reimbursement discussions in certain European countries, which positively impacted this worldwide operational growth by 16% points.

Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech Inc, a division of Johnson & Johnson, to develop, manufacture and commercialise DARZALEX.